US7642323B2
(en)
|
1997-11-06 |
2010-01-05 |
Nektar Therapeutics |
Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
|
US6448369B1
(en)
*
|
1997-11-06 |
2002-09-10 |
Shearwater Corporation |
Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
|
DK1656952T3
(da)
|
1998-10-16 |
2014-01-20 |
Biogen Idec Inc |
Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
|
IL142350A0
(en)
|
1998-10-16 |
2002-03-10 |
Biogen Inc |
Interferon-beta fusion proteins and pharmaceutical compositions containing the same
|
WO2001046291A1
(en)
*
|
1999-12-22 |
2001-06-28 |
Shearwater Corporation |
Sterically hindered derivatives of water soluble polymers
|
AU2001238595A1
(en)
*
|
2000-02-22 |
2001-09-03 |
Shearwater Corporation |
N-maleimidyl polymer derivatives
|
US7053150B2
(en)
|
2000-12-18 |
2006-05-30 |
Nektar Therapeutics Al, Corporation |
Segmented polymers and their conjugates
|
SI1436012T1
(en)
|
2001-10-18 |
2018-03-30 |
Nektar Therapeutics |
Polymer conjugates of opioid antagonists
|
MEP35608A
(en)
|
2002-01-18 |
2011-02-10 |
Biogen Idec Inc |
Polyalkylene polymer compounds and uses thereof
|
PL375265A1
(en)
*
|
2002-07-24 |
2005-11-28 |
F.Hoffmann-La Roche Ag |
Polyalkylene glycol acid additives
|
KR100974843B1
(ko)
*
|
2002-09-09 |
2010-08-11 |
넥타르 테라퓨틱스 |
수용성 중합체 알카날
|
CA2497980C
(en)
|
2002-09-09 |
2011-06-21 |
Nektar Therapeutics Al, Corporation |
Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
|
US20060014248A1
(en)
*
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
US7553930B2
(en)
*
|
2003-01-06 |
2009-06-30 |
Xencor, Inc. |
BAFF variants and methods thereof
|
US20050130892A1
(en)
*
|
2003-03-07 |
2005-06-16 |
Xencor, Inc. |
BAFF variants and methods thereof
|
US20050221443A1
(en)
*
|
2003-01-06 |
2005-10-06 |
Xencor, Inc. |
Tumor necrosis factor super family agonists
|
US20090123367A1
(en)
*
|
2003-03-05 |
2009-05-14 |
Delfmems |
Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
*
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
BRPI0408116B1
(pt)
|
2003-03-05 |
2022-09-20 |
Halozyme, Inc |
Polipeptídeos de hialuronidase solúveis conjugados a polímero, composições farmacêuticas compreendendo polipeptídeos ph20 solúveis, seus usos e processo de preparação, e ácidos nucléicos que codificam polipeptídeos de hialuronidase solúveis
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
US7642340B2
(en)
|
2003-03-31 |
2010-01-05 |
Xencor, Inc. |
PEGylated TNF-α variant proteins
|
US7587286B2
(en)
*
|
2003-03-31 |
2009-09-08 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
US8513147B2
(en)
|
2003-06-19 |
2013-08-20 |
Eastman Chemical Company |
Nonwovens produced from multicomponent fibers
|
US7892993B2
(en)
|
2003-06-19 |
2011-02-22 |
Eastman Chemical Company |
Water-dispersible and multicomponent fibers from sulfopolyesters
|
US20040260034A1
(en)
|
2003-06-19 |
2004-12-23 |
Haile William Alston |
Water-dispersible fibers and fibrous articles
|
US7482376B2
(en)
*
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
EP1648284A4
(de)
|
2003-07-18 |
2011-12-28 |
Broncus Tech Inc |
Vorrichtungen zur aufrechterhaltung der durchgängigkeit von operativ geschaffenen kanälen in gewebe
|
CN1852740B
(zh)
*
|
2003-09-17 |
2011-05-11 |
耐科塔医药公司 |
多支链聚合物的药物前体
|
US8394365B2
(en)
|
2003-09-17 |
2013-03-12 |
Nektar Therapeutics |
Multi-arm polymer prodrugs
|
WO2005035564A2
(en)
|
2003-10-10 |
2005-04-21 |
Xencor, Inc. |
Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
|
US20060182692A1
(en)
*
|
2003-12-16 |
2006-08-17 |
Fishburn C S |
Chemically modified small molecules
|
AU2004299138B2
(en)
*
|
2003-12-16 |
2010-03-25 |
Nektar Therapeutics |
Chemically Modified Small Molecules
|
JP2007521338A
(ja)
*
|
2004-01-07 |
2007-08-02 |
アンビット バイオサイエンシス コーポレーション |
共役化された低分子
|
CA2553528C
(en)
*
|
2004-01-21 |
2012-12-04 |
Nektar Therapeutics Al, Corporation |
Method of preparing propionic acid-terminated polymers
|
BRPI0507169A
(pt)
*
|
2004-02-02 |
2007-06-26 |
Ambrx Inc |
polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
|
CA2557782A1
(en)
*
|
2004-03-17 |
2005-10-06 |
Eli Lilly And Company |
Glycol linked fgf-21 compounds
|
US8470315B2
(en)
*
|
2004-04-13 |
2013-06-25 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
JP2008503217A
(ja)
*
|
2004-06-18 |
2008-02-07 |
アンブレツクス・インコーポレイテツド |
新規抗原結合ポリペプチド及びそれらの使用
|
JP2008506703A
(ja)
|
2004-07-14 |
2008-03-06 |
ユニバーシティ オブ ユタ リサーチ ファウンデーション |
ネトリン関連化合物および用途
|
AU2005327906B2
(en)
*
|
2004-07-21 |
2010-05-13 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
CA2584510C
(en)
*
|
2004-10-25 |
2013-05-28 |
Intezyne Technologies, Incorporated |
Heterobifunctional poly(ethylene glycol) and uses thereof
|
US7619007B2
(en)
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
CA2590429C
(en)
|
2004-12-22 |
2014-10-07 |
Ambrx, Inc. |
Compositions of aminoacyl-trna synthetase and uses thereof
|
NZ555206A
(en)
|
2004-12-22 |
2010-09-30 |
Ambrx Inc |
Methods for expression and purification of recombinant human growth hormone
|
EP1836314B1
(de)
|
2004-12-22 |
2012-01-25 |
Ambrx, Inc. |
Modifiziertes menschliches wachstumshormon
|
CA2594561C
(en)
|
2004-12-22 |
2014-12-23 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
WO2006089228A2
(en)
*
|
2005-02-16 |
2006-08-24 |
Nektar Therapeutics Al, Corporation |
Conjugates of an epo moiety and a polymer
|
WO2006102659A2
(en)
*
|
2005-03-23 |
2006-09-28 |
Nektar Therapeutics Al, Corporation |
CONJUGATES OF AN hGH MOIETY AND A POLYMER
|
DK1874282T3
(da)
|
2005-04-06 |
2010-10-25 |
Adamas Pharmaceuticals Inc |
Fremgangsmåder og præparater til behandling af CNS lidelser
|
KR101011081B1
(ko)
|
2005-05-13 |
2011-01-25 |
일라이 릴리 앤드 캄파니 |
Peg화된 glp-1 화합물
|
WO2006130799A2
(en)
*
|
2005-06-01 |
2006-12-07 |
Alza Corporation |
Bioconjugation reactions for acylating polyethlene glycol reagents
|
CN103030690A
(zh)
*
|
2005-06-03 |
2013-04-10 |
Ambrx公司 |
经改良人类干扰素分子和其用途
|
US20090018029A1
(en)
|
2005-11-16 |
2009-01-15 |
Ambrx, Inc. |
Methods and Compositions Comprising Non-Natural Amino Acids
|
CA2882445A1
(en)
*
|
2005-12-14 |
2007-06-21 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
US7671067B2
(en)
*
|
2006-02-09 |
2010-03-02 |
Enzon Pharmaceuticals, Inc. |
Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
|
US7462627B2
(en)
*
|
2006-02-09 |
2008-12-09 |
Enzon Pharmaceuticals, Inc. |
Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
|
DK2001518T3
(da)
*
|
2006-03-30 |
2013-10-07 |
Palatin Technologies Inc |
Cykliske natriuretiske peptidfremstillinger
|
US7795221B2
(en)
*
|
2006-03-30 |
2010-09-14 |
Palatin Technologies, Inc. |
Linear natriuretic peptide constructs
|
US8580746B2
(en)
*
|
2006-03-30 |
2013-11-12 |
Palatin Technologies, Inc. |
Amide linkage cyclic natriuretic peptide constructs
|
JP2009533347A
(ja)
|
2006-04-07 |
2009-09-17 |
ネクター セラピューティックス エイエル,コーポレイション |
抗TNFα抗体の複合体
|
WO2007124461A2
(en)
|
2006-04-20 |
2007-11-01 |
Amgen Inc. |
Glp-1 compounds
|
US7560588B2
(en)
|
2006-04-27 |
2009-07-14 |
Intezyne Technologies, Inc. |
Poly(ethylene glycol) containing chemically disparate endgroups
|
EP2044097A4
(de)
|
2006-06-23 |
2010-10-06 |
Quintessence Biosciences Inc |
Modifizierte ribonukleasen
|
WO2008010991A2
(en)
*
|
2006-07-17 |
2008-01-24 |
Quintessence Biosciences, Inc. |
Methods and compositions for the treatment of cancer
|
JP5840345B2
(ja)
|
2006-09-08 |
2016-01-06 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
修飾ヒト血漿ポリペプチドまたは修飾ヒトFc足場タンパク質ならびにこれらの利用
|
AU2007292892B9
(en)
|
2006-09-08 |
2013-02-28 |
Ambrx, Inc. |
Hybrid suppressor tRNA for vertebrate cells
|
WO2008030614A2
(en)
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Suppressor trna transcription in vertebrate cells
|
CA2669541C
(en)
|
2006-11-30 |
2014-11-18 |
Nektar Therapeutics Al, Corporation |
Method for preparing a polymer conjugate
|
KR101160385B1
(ko)
|
2007-01-18 |
2012-07-10 |
일라이 릴리 앤드 캄파니 |
페길화된 Aβ FAB
|
RU2009133793A
(ru)
*
|
2007-02-09 |
2011-03-20 |
Энзон Фармасьютикалз, Инк. (Us) |
Лечение резистентных или невосприимчивых форм рака конъюгатами 7-этил-10-гидроксикампотецина с множеством ответвлений цепи
|
KR101476472B1
(ko)
|
2007-03-30 |
2015-01-05 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
JP2010525821A
(ja)
|
2007-05-02 |
2010-07-29 |
アンブルックス,インコーポレイテッド |
修飾IFNβポリペプチドおよびこれらの使用
|
KR100979462B1
(ko)
|
2007-08-03 |
2010-09-02 |
한국화학연구원 |
안트라사이클라인계 항암약물 봉입용 리포솜 및 이의제조방법
|
WO2009048909A1
(en)
*
|
2007-10-08 |
2009-04-16 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapies
|
DK2217265T3
(en)
|
2007-11-20 |
2017-07-03 |
Ambrx Inc |
Modified insulin polypeptides and their use
|
CN103694337B
(zh)
|
2008-02-08 |
2016-03-02 |
Ambrx公司 |
经修饰瘦素多肽和其用途
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
WO2009128917A2
(en)
|
2008-04-14 |
2009-10-22 |
Halozyme, Inc. |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
EP3225248B1
(de)
|
2008-07-23 |
2023-06-07 |
Ambrx, Inc. |
Modifizierte bovine g-csf-polypeptide und ihre verwendung
|
CN102159250B
(zh)
|
2008-08-11 |
2014-08-06 |
尼克塔治疗公司 |
多臂的聚合烷酸酯偶联物
|
EP2328619B1
(de)
*
|
2008-08-22 |
2016-12-07 |
Baxalta GmbH |
Polymere benzyl-carbonat-derivate
|
TW201010732A
(en)
*
|
2008-08-29 |
2010-03-16 |
Enzon Pharmaceuticals Inc |
Method of treating RAS associated cancer
|
EP2331139B1
(de)
*
|
2008-09-11 |
2019-04-17 |
Nektar Therapeutics |
Polymer-alpha-hydroxy-aldehyd und keton-reagenzien und konjugationsverfahren
|
WO2010033227A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of thymosin alpha 1 peptides
|
WO2010033221A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of protegrin peptides
|
WO2010033240A2
(en)
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Carbohydrate-based drug delivery polymers and conjugates thereof
|
US20110237524A1
(en)
*
|
2008-09-19 |
2011-09-29 |
Nektar Therapeutics |
Polymer conjugates of aod-like peptides
|
WO2010033216A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of nesiritide peptides
|
WO2010033218A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of osteocalcin peptides
|
EP2340047A1
(de)
*
|
2008-09-19 |
2011-07-06 |
Nektar Therapeutics |
Polymerkonjugate von kiss1-peptiden
|
WO2010033223A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of opioid growth factor peptides
|
US20110171164A1
(en)
*
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of glp-2-like peptides
|
EP2334338A2
(de)
*
|
2008-09-19 |
2011-06-22 |
Nektar Therapeutics |
Polymerkonjugate von c-peptiden
|
EP2334333A1
(de)
*
|
2008-09-19 |
2011-06-22 |
Nektar Therapeutics |
Polymerkonjugate von v681-artigen peptiden
|
WO2010033222A2
(en)
*
|
2008-09-19 |
2010-03-25 |
Netkar Therapeutics |
Polymer conjugates of ziconotide peptides
|
KR20110063457A
(ko)
|
2008-09-23 |
2011-06-10 |
넥타르 테라퓨틱스 |
대상에서의 지속적 치료 약물 농도 달성을 위한 조성물 및 방법
|
KR101732054B1
(ko)
|
2008-09-26 |
2017-05-02 |
암브룩스, 인코포레이티드 |
비천연 아미노산 복제 의존성 미생물 및 백신
|
AU2009296397B2
(en)
|
2008-09-26 |
2012-11-08 |
Ambrx Inc. |
Modified animal erythropoietin polypeptides and their uses
|
JP2012504423A
(ja)
|
2008-10-01 |
2012-02-23 |
クインテッセンス バイオサイエンシズ,インコーポレーテッド |
治療用リボヌクレアーゼ
|
JP2012506380A
(ja)
*
|
2008-10-21 |
2012-03-15 |
エンゾン ファーマシューティカルズ,インコーポレーテッド |
7−エチル−10−ヒドロキシカンプトテシンのマルチアーム型ポリマーコンジュゲートによる神経芽腫の治療
|
US8927249B2
(en)
|
2008-12-09 |
2015-01-06 |
Halozyme, Inc. |
Extended soluble PH20 polypeptides and uses thereof
|
US8512519B2
(en)
|
2009-04-24 |
2013-08-20 |
Eastman Chemical Company |
Sulfopolyesters for paper strength and process
|
JP5734985B2
(ja)
|
2009-09-17 |
2015-06-17 |
バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA |
ヒアルロニダーゼおよび免疫グロブリンの安定な共製剤およびそれらの使用方法
|
DE102009045969B4
(de)
|
2009-10-23 |
2019-01-31 |
Technische Universität Bergakademie Freiberg |
Verfahren und Mittel zur Spaltung von Estern, Amiden und Thioestern der Ameisensäure
|
US8741343B2
(en)
|
2009-12-02 |
2014-06-03 |
Adamas Pharmaceuticals, Inc. |
Method of administering amantadine prior to a sleep period
|
EP2805964A1
(de)
|
2009-12-21 |
2014-11-26 |
Ambrx, Inc. |
Modifizierte Rinder-Somatotropinpolypeptide und deren Verwendungen
|
NZ600363A
(en)
|
2009-12-21 |
2014-07-25 |
Ambrx Inc |
Modified porcine somatotropin polypeptides and their uses
|
AR079344A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
|
JO2976B1
(en)
|
2009-12-22 |
2016-03-15 |
ايلي ليلي اند كومباني |
Axentomodulin polypeptide
|
JP2013533217A
(ja)
|
2010-05-17 |
2013-08-22 |
セビックス・インコーポレイテッド |
Peg化c−ペプチド
|
WO2012004007A1
(en)
|
2010-07-09 |
2012-01-12 |
Fresenius Kabi Deutschland Gmbh |
Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
|
WO2012004009A1
(en)
|
2010-07-09 |
2012-01-12 |
Fresenius Kabi Deutschland Gmbh |
Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
|
ES2661089T3
(es)
|
2010-07-20 |
2018-03-27 |
Halozyme Inc. |
Métodos de tratamiento o prevención de los efectos secundarios adversos asociados con la administración de un agente anti-hialuronano
|
DK2605789T3
(da)
|
2010-08-17 |
2019-09-16 |
Ambrx Inc |
Modificerede relaxinpolypeptider og anvendelser deraf
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
ES2819305T3
(es)
|
2010-09-30 |
2021-04-15 |
Astrazeneca Ab |
Combinación de un conjugado de naloxol-peg y un agonista opioide
|
US20120183861A1
(en)
|
2010-10-21 |
2012-07-19 |
Eastman Chemical Company |
Sulfopolyester binders
|
WO2012054822A1
(en)
|
2010-10-22 |
2012-04-26 |
Nektar Therapeutics |
Pharmacologically active polymer-glp-1 conjugates
|
TWI557135B
(zh)
|
2010-11-03 |
2016-11-11 |
介控生化科技公司 |
經修飾之第九因子多胜肽及其用途
|
CA2817994C
(en)
|
2010-12-01 |
2019-01-22 |
Huntsman Petrochemical Llc |
Sterically hindered amines and associated methods
|
WO2012088445A1
(en)
|
2010-12-22 |
2012-06-28 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
|
US20130331443A1
(en)
|
2010-12-22 |
2013-12-12 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of taxane-based compounds
|
WO2012109387A1
(en)
|
2011-02-08 |
2012-08-16 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
WO2012174478A2
(en)
|
2011-06-17 |
2012-12-20 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
US9993529B2
(en)
|
2011-06-17 |
2018-06-12 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
CA2839512C
(en)
|
2011-06-17 |
2018-01-02 |
Halozyme, Inc. |
Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
|
WO2013040501A1
(en)
|
2011-09-16 |
2013-03-21 |
Pharmathene, Inc. |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
|
JP6162707B2
(ja)
|
2011-10-24 |
2017-07-12 |
ハロザイム インコーポレイテッド |
抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
|
CA2855770A1
(en)
|
2011-11-17 |
2013-05-23 |
Cebix Ab |
Pegylated c-peptide
|
EP3130347B1
(de)
|
2011-12-30 |
2019-09-18 |
Halozyme, Inc. |
Ph20-polypeptidvarianten, formulierungen und verwendungen davon
|
US8882963B2
(en)
|
2012-01-31 |
2014-11-11 |
Eastman Chemical Company |
Processes to produce short cut microfibers
|
US9913822B2
(en)
|
2012-04-04 |
2018-03-13 |
Halozyme, Inc. |
Combination therapy with an anti-hyaluronan agent and therapeutic agent
|
KR102172897B1
(ko)
|
2012-06-08 |
2020-11-02 |
서트로 바이오파마, 인크. |
부위-특이적 비-천연 아미노산 잔기를 포함하는 항체, 그의 제조 방법 및 그의 사용 방법
|
WO2014004639A1
(en)
|
2012-06-26 |
2014-01-03 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
PL3584255T3
(pl)
|
2012-08-31 |
2022-05-16 |
Sutro Biopharma, Inc. |
Modyfikowane aminokwasy zawierające grupę azydkową
|
US9278124B2
(en)
|
2012-10-16 |
2016-03-08 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
US9617685B2
(en)
|
2013-04-19 |
2017-04-11 |
Eastman Chemical Company |
Process for making paper and nonwoven articles comprising synthetic microfiber binders
|
US10154971B2
(en)
|
2013-06-17 |
2018-12-18 |
Adamas Pharma, Llc |
Methods of administering amantadine
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ph20玻尿酸酶變異體及其用途
|
WO2015006555A2
(en)
|
2013-07-10 |
2015-01-15 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
EP3055298B1
(de)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modifizierte aminosäuren mit funktionellen tetrazingruppen, verfahren zur herstellung und verfahren zu deren verwendung
|
CN105934257B
(zh)
|
2013-12-06 |
2020-10-09 |
韩捷 |
用于含氮和羟基的药物的生物可逆引入基团
|
US9605126B2
(en)
|
2013-12-17 |
2017-03-28 |
Eastman Chemical Company |
Ultrafiltration process for the recovery of concentrated sulfopolyester dispersion
|
US9598802B2
(en)
|
2013-12-17 |
2017-03-21 |
Eastman Chemical Company |
Ultrafiltration process for producing a sulfopolyester concentrate
|
JP7059003B2
(ja)
|
2014-05-14 |
2022-04-25 |
トラスティーズ・オブ・ダートマス・カレッジ |
脱免疫化リゾスタフィン及び使用方法
|
PL3186281T3
(pl)
|
2014-08-28 |
2019-10-31 |
Halozyme Inc |
Terapia skojarzona enzymem rozkładającym hialuronian i inhibitorem punktu kontrolnego odpowiedzi immunologicznej
|
BR112017007765B1
(pt)
|
2014-10-14 |
2023-10-03 |
Halozyme, Inc |
Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
|
UY36370A
(es)
|
2014-10-24 |
2016-04-29 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Polipéptidos fgf-21 modificados y sus usos
|
CN109562167A
(zh)
|
2016-08-09 |
2019-04-02 |
伊莱利利公司 |
联合治疗
|
ES2963839T3
(es)
|
2017-02-08 |
2024-04-02 |
Bristol Myers Squibb Co |
Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
|
CA3177086A1
(en)
|
2017-06-22 |
2018-12-27 |
Catalyst Biosciences, Inc. |
Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
|
US11491212B1
(en)
|
2017-09-27 |
2022-11-08 |
Catalyst Biosciences, Inc. |
Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
|
EP3688007A1
(de)
|
2017-09-27 |
2020-08-05 |
The University of York |
Biokonjugation von polypeptiden
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
JP7441826B2
(ja)
|
2018-09-11 |
2024-03-01 |
アンブルックス,インコーポレイテッド |
インターロイキン-2ポリペプチド抱合物およびその使用
|
AU2019361206A1
(en)
|
2018-10-19 |
2021-06-03 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
MX2021007843A
(es)
|
2018-12-28 |
2021-08-11 |
Vertex Pharma |
Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso.
|
JP2022520792A
(ja)
|
2019-02-12 |
2022-04-01 |
アンブルックス,インコーポレイテッド |
抗体-tlrアゴニストコンジュゲートを含有する組成物、その方法、及び使用
|
US11377173B1
(en)
|
2019-07-30 |
2022-07-05 |
Christopher T. Stanton |
Automated cover support and method
|
JP7303391B2
(ja)
|
2020-01-14 |
2023-07-04 |
シンセカイン インコーポレイテッド |
バイアス型il2ムテイン、方法、および組成物
|
WO2021154414A2
(en)
|
2020-01-29 |
2021-08-05 |
Catalyst Biosciences, Inc. |
Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
|
CA3174114A1
(en)
|
2020-03-11 |
2021-09-16 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
EP3954393A1
(de)
|
2020-08-13 |
2022-02-16 |
Bioasis Technologies Inc. |
Kombinationstherapien zur verabreichung über die blut-hirn-schranke hinweg
|
JP2023538071A
(ja)
|
2020-08-20 |
2023-09-06 |
アンブルックス,インコーポレイテッド |
抗体-tlrアゴニストコンジュゲート、その方法及び使用
|
CA3213805A1
(en)
|
2021-04-03 |
2022-10-06 |
Feng Tian |
Anti-her2 antibody-drug conjugates and uses thereof
|